SCHEDULE: Alzamend Neuro: Ault Entities Adjust Holdings

Milton C. Ault, III and affiliated entities updated their beneficial ownership in Alzamend Neuro, Inc., disclosing significant common stock sales by Ault Lending, LLC.

Summary

• Milton C. Ault, III, along with affiliated entities, reported a beneficial ownership of 306,321 shares of Alzamend Neuro, Inc. common stock, representing approximately 8.0% of the class.
• This beneficial ownership includes 1,843 shares held directly by Mr. Ault, and significant holdings through Ault Lending, LLC, Ault Life Sciences, Inc., Ault Life Sciences Fund, LLC, and Hyperscale Data, Inc.
• Ault Lending, LLC converted 928 shares of Series B Convertible Preferred Stock into common stock between September 17, 2025, and October 1, 2025, at a conversion price of $1,000.00 per preferred share.
• Ault Lending, LLC subsequently sold a total of 499,990 shares of common stock between September 17, 2025, and October 3, 2025, with prices ranging from $2.3090 to $2.4673 per share.
• As of October 2, 2025, the total number of Shares outstanding was reported as 3,539,861.
• Other reporting persons, including William B. Horne, Henry C.W. Nisser, Kenneth S. Cragun, and David J. Katzoff, reported beneficial ownership ranging from 0.0% to 0.1%, primarily consisting of direct shares and stock options.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the significant selling activity by Ault Lending, LLC, a major beneficial owner. While Mr. Ault and related entities still hold a substantial stake, the recent sales, especially after converting preferred stock, suggest a reduction in confidence or a strategic exit from a portion of their holdings, which can be a bearish signal for the market.

Positives

• Milton C. Ault, III and affiliated entities collectively maintain a significant beneficial ownership stake of 8.0% in Alzamend Neuro, Inc., indicating continued interest in the company's performance.

Negatives

• Ault Lending, LLC engaged in substantial sales of common stock, totaling 499,990 shares, over a short period (September 17, 2025, to October 3, 2025), following conversions of preferred stock.
• The selling activity by a major beneficial owner could signal a reduction in conviction or a need for liquidity, potentially exerting downward pressure on the stock price.

Risks

• Significant selling by a major beneficial owner, such as Ault Lending, LLC, may lead to increased market supply and potential downward pressure on Alzamend Neuro's common stock price.
• A reduction in the beneficial ownership percentage by key individuals and affiliated entities could be perceived as a decrease in insider confidence in the company's future prospects.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Milton C. Ault, III is deemed to beneficially own shares held by Hyperscale Data, Inc., Ault Life Sciences, Inc., Ault Life Sciences Fund, LLC, and Ault Lending, LLC due to his relationships with these entities.
• Hyperscale Data, Inc. is deemed to beneficially own shares held by Ault Lending, LLC due to its relationship with the entity.
• Ault Lending, LLC engaged in conversions of Series B Convertible Preferred Stock and subsequent sales of common stock, impacting the overall beneficial ownership of the Ault-affiliated group.

Stakeholder Impact

• Shareholders may experience decreased confidence in the company due to the significant selling activity by a major beneficial owner, potentially leading to downward pressure on the stock price.
• The actions of these related parties, particularly Ault Lending, LLC, directly influence the market dynamics and perception of Alzamend Neuro's stock.

Key Dates

Recommendation

The substantial selling of common stock by Ault Lending, LLC, an entity closely associated with a major beneficial owner (Milton C. Ault, III), after converting preferred stock, is a strong negative signal. This action suggests a reduction in conviction or a strategic divestment, which typically precedes or contributes to downward pressure on the stock price. A seasoned investor would likely interpret this as a reason to reduce or exit their position.

Keywords

Alzamend Neuro, AZN, Milton C. Ault III, Ault Lending, Hyperscale Data, Beneficial Ownership, Insider Sales, Common Stock, Preferred Stock, Warrants, SEC Filing, Schedule 13D